 LEIDEN, Netherlands CAMBRIDGE, Mass., Feb. 25, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq: PRQR the Company, a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases IRDs, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a business update. 